Robert G Maki Selected Research

Dermatofibrosarcoma

9/2011	Pigmentary changes in a patient treated with imatinib.
2/2011	Dermatofibrosarcoma protuberans (DFSP): predictors of recurrence and the use of systemic therapy.
6/2007	Opportunities for improving the therapeutic ratio for patients with sarcoma.
4/2004	Role of chemotherapy in patients with soft tissue sarcomas.
8/2002	Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Robert G Maki Research Topics

Disease

80	Neoplasms (Cancer) 04/2022 - 08/2002
76	Sarcoma (Soft Tissue Sarcoma) 01/2022 - 08/2002
33	Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) 11/2020 - 08/2002
16	Liposarcoma 11/2020 - 10/2004
14	Disease Progression 01/2022 - 05/2005
14	Leiomyosarcoma 12/2019 - 06/2007
9	Hemangiosarcoma (Angiosarcoma) 01/2022 - 05/2005
9	Neoplasm Metastasis (Metastasis) 01/2019 - 08/2002
8	Synovial Sarcoma (Synovioma) 01/2022 - 06/2007
8	Osteosarcoma (Osteogenic Sarcoma) 01/2019 - 08/2003
6	Ewing Sarcoma (Sarcoma, Ewing) 01/2022 - 03/2007
6	Aggressive Fibromatosis (Desmoid) 01/2022 - 06/2007
5	Fatigue 01/2022 - 03/2012
5	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 07/2015 - 08/2002
5	Dermatofibrosarcoma 09/2011 - 08/2002
4	Hypertension (High Blood Pressure) 01/2022 - 02/2008
4	Rhabdomyosarcoma 01/2021 - 03/2007
4	Neurofibrosarcoma (MPNST) 01/2019 - 07/2009
4	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 10/2011 - 10/2010
3	Nausea 01/2022 - 03/2012
3	Genetic Translocation (Chromosomal Translocation) 11/2012 - 08/2002
2	Histiocytic Sarcoma 04/2022 - 11/2015
2	Diarrhea 01/2022 - 12/2018
2	Vomiting 01/2022 - 06/2012
2	Epistaxis (Nosebleed) 01/2022 - 01/2009
2	Anemia 01/2022 - 01/2017
2	Lymphoma (Lymphomas) 04/2020 - 01/2018
2	Cardiotoxicity 01/2020 - 10/2005
2	Thrombocytopenia (Thrombopenia) 01/2017 - 01/2009
2	Pigmented Villonodular Synovitis 01/2015 - 03/2012
2	Neutropenia 06/2012 - 03/2012
2	Fibroma (Fibromatosis) 06/2011 - 05/2010
2	Malignant Fibrous Histiocytoma 07/2009 - 08/2007
1	Myxoid Liposarcoma 01/2022
1	Kaposi Sarcoma (Kaposi's Sarcoma) 01/2022
1	Headache (Headaches) 01/2022

Drug/Important Bio-Agent (IBA)

35	Imatinib Mesylate (Gleevec)FDA Link 01/2022 - 08/2002
18	Phosphotransferases (Kinase)IBA 01/2022 - 08/2007
13	Sunitinib (Sutent)FDA Link 01/2019 - 10/2006
11	Dacarbazine (DIC)FDA LinkGeneric 12/2019 - 04/2004
11	TrabectedinIBA 12/2019 - 10/2002
10	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2022 - 04/2004
9	Tyrosine Kinase InhibitorsIBA 01/2019 - 04/2004
8	AnthracyclinesIBA 04/2020 - 05/2010
7	Biological ProductsIBA 01/2022 - 05/2005
7	Sorafenib (BAY 43-9006)FDA Link 01/2022 - 08/2007
7	Pharmaceutical PreparationsIBA 01/2020 - 10/2002
7	Ifosfamide FDA LinkGeneric 01/2017 - 04/2004
6	pazopanib FDA Link 01/2022 - 05/2015
6	Gemcitabine FDA Link 01/2020 - 04/2004
6	CrizotinibIBA 01/2020 - 10/2010
6	DNA (Deoxyribonucleic Acid)IBA 06/2019 - 01/2008
6	Proteins (Proteins, Gene)FDA Link 05/2019 - 07/2003
5	regorafenibIBA 11/2020 - 01/2013
4	eribulin FDA Link 01/2019 - 10/2011
4	Monoclonal AntibodiesIBA 01/2019 - 11/2010
4	Docetaxel (Taxotere)FDA Link 01/2019 - 07/2007
4	Sirolimus (Rapamycin)FDA Link 02/2014 - 06/2007
3	Immune Checkpoint InhibitorsIBA 04/2020 - 07/2016
3	AntigensIBA 04/2020 - 07/2006
3	Antineoplastic Agents (Antineoplastics)IBA 01/2020 - 10/2002
3	RNA (Ribonucleic Acid)IBA 06/2019 - 08/2003
3	Insulin-Like PeptidesIBA 01/2013 - 11/2010
3	tyrosine receptor (receptor, tyrosine)IBA 01/2011 - 02/2008
2	IpilimumabIBA 04/2020 - 01/2013
2	Biomarkers (Surrogate Marker)IBA 01/2020 - 12/2019
2	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 10/2018 - 10/2010
2	Bevacizumab (Avastin)FDA Link 01/2015 - 10/2005
2	teprotumumabIBA 08/2014 - 12/2011
2	Phosphoric Monoester Hydrolases (Phosphatases)IBA 02/2014 - 12/2012
2	TensinsIBA 02/2014 - 12/2012
2	Transcription Factors (Transcription Factor)IBA 11/2012 - 03/2012
2	Paclitaxel (Taxol)FDA LinkGeneric 07/2012 - 05/2005
2	Cyclin-Dependent Kinases (cdk Proteins)IBA 05/2012 - 03/2005
2	Anaplastic Lymphoma KinaseIBA 05/2011 - 10/2010
2	Fluorouracil (Carac)FDA LinkGeneric 05/2009 - 03/2005
2	VaccinesIBA 08/2007 - 07/2006
2	AntibodiesIBA 07/2006 - 07/2003
2	CollagenIBA 05/2006 - 08/2002
2	Alkaline PhosphataseIBA 05/2006 - 09/2005
1	carotuximabIBA 01/2022
1	atezolizumabIBA 01/2022
1	IminesIBA 01/2022
1	Lenalidomide (CC 5013)FDA Link 01/2022
1	Estrogen ReceptorsIBA 01/2022
1	B7-H1 AntigenIBA 01/2022
1	Methotrexate (Mexate)FDA LinkGeneric 01/2022
1	Vinca AlkaloidsIBA 01/2022
1	brigatinibIBA 01/2022
1	NivolumabIBA 04/2020

Therapy/Procedure

59	Therapeutics 04/2022 - 08/2002
38	Drug Therapy (Chemotherapy) 01/2022 - 04/2004
8	Radiotherapy 02/2021 - 03/2007
4	Immunotherapy 04/2022 - 07/2006
4	Adjuvant Chemotherapy 04/2022 - 04/2004
2	Neoadjuvant Therapy 06/2012 - 08/2009
2	Aftercare (After-Treatment) 02/2011 - 01/2008
1	Metastasectomy 01/2022
1	Conservative Treatment 02/2021
1	Palliative Care (Palliative Therapy) 02/2021